Drug Trial Radar · NCT05751798
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
41
Planned (sponsor's estimate)
Start
Dec 20, 2022
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- OSE ImmunotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.
Conditions
- Solid Advanced Tumor
- Lymphoma
- NSCLC (Non-small Cell Lung Cancer)
Interventions
Part A: OSE-279 100mgDrug
Human IgG4 mAb against PD-1
Part A: OSE-279 300mgDrug
Human IgG4 mAb against PD-1
Part A: OSE-279 600mgDrug
Human IgG4 mAb against PD-1
Part B: OSE-279 600 mg and OSE2101Drug
OSE-279: OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine
Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positiveDrug
OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine
Part C: OSE-279 600 mg - HLA-A2 positifDrug
OSE-279: Human IgG4 mAb against PD-1
Part C: OSE-279 600 mg - HLA-A2 negativeDrug
OSE-279: Human IgG4 mAb against PD-1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Occurrence of dose limiting toxicity (DLT). Part B: Safety and tolerability of the combination OSE-279/OSE2101. Part C: Overall response rate (ORR) of the combination OSE-279/OSE2101Time frame: Part A: DLT observation period is defined as the first 21 days after receiving the 1st injection of OSE-279 (Cycle 1) Part B: DLT observation period is defined as the first 6 weeks after receiving the combinaison Part C: Best response
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Institut Jules Bordet
Anderlecht, Belgium · Recruiting
Antwerp University Hospital
Edegem, Belgium · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Hopital Saint Joseph
Paris, France · Recruiting
Centre Eugène Marquis
Rennes, France · Completed
Institut de Cancerologie de l'Ouest
Saint-Herblain, France · Recruiting
Oncopole
Toulouse, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
University Hospital A Coruña Biomedical Research Institute (INIBIC)
A Coruña, Spain · Recruiting
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI)
Girona, Spain · Recruiting
Hospital Regional Universitario de Málaga
Málaga, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.